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Background: Little is known about depressive symptoms in heart failure with preserved ejection fraction (HFpEF, EF ≥50%). We aimed to assess 
the prevalence of depression, to clarify the impact of depressive symptoms upon clinical outcomes, and to identify factors associated with these 
symptoms in HF with reduced EF (HFrEF, EF < 50%) and HFpEF. 
Methods and Results: A total of 106 HF outpatients were enrolled. Of them, 61 (58%) were HFpEF. Most patients were male (HFrEF 80%, HFpEF 
70%) and the mean of plasma B-type natriuretic peptide (BNP) level in the HFrEF group was similar to that in the HFpEF group (164.8±232.8 
vs. 98.7±94.8 pg/mL). HFrEF patients were treated more frequently with beta-blockers compared with HFpEF patients (71% vs. 43%, P = 0.004). 
Depressive symptoms were assessed by Center for Epidemiologic Studies Depression Scale (CES-D). The prevalence of depression (CES-D score 
≥16), and CES-D score did not significantly differ between HFrEF and HFpEF (24% vs. 25%, 14.1±8.3 vs. 12.1±8.3, respectively). During the 2-year 
follow-up, depressed patients had more cardiac death or HF hospitalization in HFrEF (55% vs. 12%, P = 0.002) and HFpEF (35% vs. 11%, P = 
0.031). Cox proportional hazard analysis revealed that a higher CES-D score, indicating increased depressive symptoms, predicted cardiac events 
independent of BNP in HFrEF (hazard ratio [HR] 1.07, 95% confidence interval [CI] 1.01-1.13) and HFpEF (HR 1.09, 95%CI 1.04-1.15). Increased 
depressive symptoms were also significantly associated with higher mortality in HFrEF and HFpEF. Multiple regression analyses adjusted for BNP 
showed that independent predictors of depressive symptoms were non-usage of beta-blockers and being widowed or divorced in HFrEF patients. On 
the other hand, usage of warfarin was the only independent risk factor for depressive symptoms in HFpEF patients. 
Conclusions: Depressive symptoms are common and predict adverse cardiac events in HFrEF and HFpEF. Although recent clinical trials using 
antidepressants have failed to find the beneficial effects, this study suggests that beta-blocker therapy reduces depressive symptoms in HFrEF. In 
contrast, treatment for depression remains to be elucidated in HFpEF. 
